about
Novel agents in the treatment of multiple myeloma: a review about the futureBMI1: A Biomarker of Hematologic MalignanciesNovel strategies to target the ubiquitin proteasome system in multiple myelomaMolecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision MedicineDrugging the unfolded protein response in acute leukemiasDevelopment of Novel Immunotherapies for Multiple MyelomaIsolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic DeviceA prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myelomaOptimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.Molecular Characteristics of High-Dose Melphalan Associated Oral Mucositis in Patients with Multiple Myeloma: A Gene Expression Study on Human MucosaSingle-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical ModelDeregulated expression of the HSP40 family members Auxilin-1 and -2 is indicative of proteostasis imbalance and predicts patient outcome in Ph(+) leukemia.Efficacy and Safety of Danshen Compound Tablets in Preventing Thalidomide-Associated Thromboembolism in Patients with Multiple Myeloma: A Multicenter Retrospective Study.Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma.Quercetin induces cell apoptosis of myeloma and displays a synergistic effect with dexamethasone in vitro and in vivo xenograft models.The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma.Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma.Gambogenic acid synergistically potentiates bortezomib-induced apoptosis in multiple myeloma.Managing multiple myeloma in elderly patients.Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.Induction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials.Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.Melphalan hydrochloride for the treatment of multiple myeloma.Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation.Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma.Primary Plasma Cell Leukemia: Identity Card 2016.CRISPR-Cas9 technology and its application in haematological disorders.Hematological approaches to multiple myeloma: trends from a Brazilian subset of hematologists. A cross-sectional study.Multiple myeloma: managing a complex blood cancer.Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis.Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.Racial disparities in treatment use for multiple myeloma.Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma.Developments in the Field of Myeloma in the Last Decade.Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference.Observational study of multiple myeloma in Latin America.'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
P2860
Q26745924-1FB0B5D1-10B7-402C-8CBD-54CE058BD12EQ26750676-CA283358-0015-4E94-8AEE-967BA5D45D0BQ26773246-4E4EA208-0F95-4BEA-A608-DFF8FCD52D77Q26799238-2DBE178B-17C3-4268-8D46-28E50980ACC8Q26801114-F827B45B-325E-411E-AEF6-F05FFB00E6D9Q28066890-648CCD1B-2B5B-412A-8902-9F3AA248A58AQ30843897-2C9E9A0C-09CB-4E6F-9D97-34A1156C6A73Q33914056-C432EA8A-A8FD-4F9B-8FA0-9E601A1CF752Q34551324-320BA4D3-7561-4CE7-BCDC-D8804EF46193Q36239520-F0796B9B-B949-4294-90B6-C7E2DF012BE8Q36245624-57679602-F4D8-4FBA-8032-940FDEF57625Q36560517-023A5551-D303-42F5-AC53-D20A47FBBA5FQ37362054-A0D1C4E3-FDAE-498E-B616-2D0E98213921Q37469859-7CD31CDF-749A-44BC-8742-4CC5D68B650FQ37564458-16CEA4D1-16E7-43BA-8F9A-527783690030Q37644252-D7E06AD0-7604-4D86-B39C-FF92DD0585EFQ37664019-7CDBA4CF-6464-49EA-9A5B-600C91A02F92Q37701514-924251E3-DEC8-48CF-AF94-8F0D47D834A2Q37738092-E53C52C1-8B9C-45C8-A84F-C9184B310493Q38605484-B01028DE-07F3-4BC1-BF2F-6A3DCA0DA166Q38612199-715CE0E0-A91B-4E37-94B7-95DD03DF9903Q38650700-7786E6F3-684C-4B89-9A0E-E3A9177E703BQ38661374-DA046F89-6AFA-4E49-8C4A-AEFA7BEDB2CFQ38662385-AB44B08A-B72C-4437-BBA7-6383F3A35817Q38704146-FF04FEE3-422A-47CF-A63E-A123065497A3Q38709050-742EE24A-B26D-4D30-87E6-96622240E38FQ38763225-DBB7E596-639D-4183-AE14-E44A59B031F0Q38781794-57D82C31-6D96-425A-941A-B69591F73621Q38822073-797721C5-824C-408A-BAB4-58F3184144B9Q38936142-13377622-991B-45AA-ACEC-FE83D8AF994BQ38951283-F7B3A7C0-483D-437C-9897-F1BB6B7AA428Q38971754-76F9F1FE-8557-43DD-8B9C-476A4F7A7228Q38981247-0EC59BF4-F48F-4E0C-BD06-E78C10728055Q39022279-6B79EFA0-6564-4B1E-9D3C-18E182A5DDF6Q39070193-8FB7B988-E0BE-43F1-9BD9-B6A492BA8EEFQ39103567-18B077D8-1EBF-4D0F-90B4-EF16EEA8EF6AQ39134193-2373A514-E355-422E-9270-351FB54C1FB2Q39134205-56674875-62F4-40EE-A580-3F307D2F8F46Q40488479-7BF4325D-9D2B-41CD-AFFB-E9748DBAF10EQ40582501-DB3D47AA-3550-4B25-8C6E-B0105B3F5AE3
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Frontline therapy of multiple myeloma.
@en
type
label
Frontline therapy of multiple myeloma.
@en
prefLabel
Frontline therapy of multiple myeloma.
@en
P50
P1433
P1476
Frontline therapy of multiple myeloma
@en
P304
P356
10.1182/BLOOD-2014-09-568915
P407
P577
2015-04-02T00:00:00Z